Literature DB >> 12170758

Cellular and molecular biology of human melanoma.

K Satyamoorthy1, M Herlyn.   

Abstract

Melanoma develops from a series of architectural and phenotypically distinct stages and becomes progressively aggressive culminating in metastasis. Over the years, considerable progress has been made in understanding the biological, pathological and immunological aspects of human melanoma progression. Epidemiological and experimental studies have suggested that intense exposures during early childhood to UV radiation may lead to melanoma in adults, but molecular and genetic studies have revealed few autosomal abnormalities, infrequent mutational spectra and very little epistatic and epigenetic mechanisms. At the cellular level it has become clear that deregulated homeostatic control in the skin microenvironment occurs through alterations in the expression of specific proteins. These include growth factors and their receptors, adhesion molecules and their ligands, proteases and their substrates, and transcription factors and their target genes. Like in most other human tumors, there are alterations in the regulatory networks involving signal transduction in human melanoma. Appropriate models mimicking the human disease have been developed. However, these have not yet led to major advances in delineating the precise molecular determinants responsible for melanoma progression. Results from recent studies have put more impetus on identification of new molecules that promise to become better therapeutic targets. This review focuses on the most recent progress in understanding the molecular determinants of tumor progression with a particular emphasis on melanoma as a biological responder to altered homeostasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170758     DOI: 10.4161/cbt.1.1.32

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  11 in total

1.  New approaches to the biology of melanoma: a workshop of the National Institutes of Health Pathology B Study Section.

Authors:  Meenhard Herlyn; Martin Padarathsingh; Lynda Chin; Mary Hendrix; Dorothea Becker; Mark Nelson; Yves DeClerck; James McCarthy; Suresh Mohla
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 2.  Radiosensitizing properties of magnetic hyperthermia mediated by superparamagnetic iron oxide nanoparticles (SPIONs) on human cutaneous melanoma cell lines.

Authors:  Jakub Dalibor Rybka
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-06

3.  Molecular Mechanism of β-Catenin Signaling Pathway Inactivation in ETV1-Positive Prostate Cancers.

Authors:  Sharif Morsalin; Chunshu Yang; Jinbo Fang; Sampreet Reddy; Shubhalaxmi Kayarthodi; Ed Childs; Roland Matthews; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2015-09

4.  Expression of PCNA and CD44mRNA in colorectal cancer with venous invasion and its relationship to liver metastasis.

Authors:  Shu-Qiang Yue; Yan-Ling Yang; Ke-Feng Dou; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

5.  Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Authors:  Melissa A Tran; Raghavendra Gowda; Arati Sharma; Eun-Joo Park; James Adair; Mark Kester; Nadine Barrie Smith; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 6.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.

Authors:  Rajasekharan Somasundaram; Jessie Villanueva; Meenhard Herlyn
Journal:  Adv Pharmacol       Date:  2012

7.  miRNAs and Melanoma: How Are They Connected?

Authors:  Adriana Taveira da Cruz; Miriam Galvonas Jasiulionis
Journal:  Dermatol Res Pract       Date:  2011-08-10

8.  Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids.

Authors:  Joana R Viola; Diana F Rafael; Ernst Wagner; Robert Besch; Manfred Ogris
Journal:  J Drug Deliv       Date:  2013-03-25

9.  Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells.

Authors:  Sarah L Miles; Adam P Fischer; Sandeep J Joshi; Richard M Niles
Journal:  BMC Cancer       Date:  2015-11-07       Impact factor: 4.430

10.  Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation.

Authors:  Yong Sun; Hongyu Cheng; Guangjun Wang; Guojun Yu; Dawei Zhang; Yibing Wang; Wei Fan; Weixi Yang
Journal:  Oncotarget       Date:  2017-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.